Viyash Scientific announces Q3 FY26 results, approves new ESOP scheme, and management changes
Viyash Scientific Limited reported Q3 FY26 results with consolidated revenue at ₹8,584.10 crore and profit before tax at ₹1,143.30 crore. The company approved the Viyash Scientific Limited Employee Stock Option Scheme 2026, with up to 1,34,75,000 stock options. Changes in Senior Management Personnel were also approved, including the appointment of Mr. Attanti Veera Venkata Srinivasa Rao and others.
The announcement includes financial results, a new ESOP scheme which can impact future equity dilution, and changes in senior management, all of which are material events for investors.
The company reported its financial results, approved a new ESOP scheme, and made management changes, indicating operational progress and strategic planning.
Viyash Scientific Limited (formerly Sequent Scientific Limited) announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company's Board of Directors, in a meeting held on February 5, 2026, also approved the introduction of the "Viyash Scientific Limited Employee Stock Option Scheme 2026" (VSL ESOP Scheme 2026), subject to necessary approvals. This new scheme aims to align with post-merger strategic objectives and operational requirements. Additionally, the Board approved changes in Senior Management Personnel (SMP) effective February 5, 2026, following a comprehensive review of leadership roles.
New SMPs appointed include Mr. Attanti Veera Venkata Srinivasa Rao (VP, R&D (API)), Mr. Nrusimha Srinivasa Rao Bondalapati (VP, Quality & Regulatory), and Mr. Peddanna Gumudavelli (COO, Appco Pharma LLC). Mr. Pradip Natarajan will cease to be an SMP while continuing his employment. The company also disclosed the contact details of Directors/Key Managerial Personnel authorized to determine the materiality of events for disclosures.
The financial results show that for the quarter ended December 31, 2025, consolidated revenue from operations was ₹8,584.10 crore, and profit before tax was ₹1,143.30 crore. For the nine months ended December 31, 2025, consolidated revenue from operations was ₹25,003.50 crore, and profit before tax was ₹2,679.90 crore. Standalone revenue from operations for the quarter was ₹3,416.40 crore, with profit before tax at ₹106.10 crore. For the nine months ended December 31, 2025, standalone revenue was ₹10,095.70 crore, and profit before tax was ₹674.70 crore. The financial statements reflect the impact of the Composite Scheme of Amalgamation, which became effective on December 16, 2025.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.